Viridian Therapeutics, Inc.

viridiantherapeutics.com

Viridian Therapeutics, Inc.
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

MYMD PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD DRUG CANDIDATE MYMD-1 IN A METHOD OF EXTENDING LIFESPAN

MyMD | November 24, 2021

news image

MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual. “This patent is a timely addition to ...

Read More

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

news image

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

Pharmacy Market

MEDISCA CHOOSES CREATIO TO SPEED UP OPERATIONS AND INCREASE MARKET SHARE

MEDISCA | June 18, 2021

news image

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Read More

Pharmacy Market

NOBEL BIOCARE RECEIVES FDA 510(K) CLEARANCE FOR THE NOBEL BIOCARE N1™ IMPLANT SYSTEM

Envista Holdings Corporation | December 28, 2021

news image

Envista Holdings Corporation announced that the U.S. Food and Drug Administration has cleared the Nobel Biocare N1™ implant system. Boasting a biologically driven design of components and forward-thinking treatment protocols, the N1™ implant system represents a significant step forward in patient-centric implant solutions. More than an implant, N1 is a comprehensive system of dedicated instruments, prosthetic components, and surgical protocols. New features of the syst...

Read More
news image

Pharma Tech

MYMD PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD DRUG CANDIDATE MYMD-1 IN A METHOD OF EXTENDING LIFESPAN

MyMD | November 24, 2021

MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual. “This patent is a timely addition to ...

Read More
news image

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

news image

Pharmacy Market

MEDISCA CHOOSES CREATIO TO SPEED UP OPERATIONS AND INCREASE MARKET SHARE

MEDISCA | June 18, 2021

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Read More
news image

Pharmacy Market

NOBEL BIOCARE RECEIVES FDA 510(K) CLEARANCE FOR THE NOBEL BIOCARE N1™ IMPLANT SYSTEM

Envista Holdings Corporation | December 28, 2021

Envista Holdings Corporation announced that the U.S. Food and Drug Administration has cleared the Nobel Biocare N1™ implant system. Boasting a biologically driven design of components and forward-thinking treatment protocols, the N1™ implant system represents a significant step forward in patient-centric implant solutions. More than an implant, N1 is a comprehensive system of dedicated instruments, prosthetic components, and surgical protocols. New features of the syst...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us